Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06613334 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Voice-Based Biomarkers: A Novel Approach to Monitoring and Predicting Schizophrenia Relapses

Study acronym: OBSERVSPEECH
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Oct 4, 2026 → Apr 2027
See other at-risk trials from Centre Hospitalier St Anne

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Oct 4, 2026 to Apr 2027 Show 4 more changesShow less
    • Study completion pushed from Oct 4, 2026 to Oct 2027
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 7 of 14 entries
    • Site details revised at 1 of 2 sites
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Primary and study completion dates: Sep 25, 2026 to Oct 4, 2026
    • Start date changed from estimate of Sep 25, 2024 to Oct 4, 2024
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive impairment and social isolation. Treatments with antipsychotics have proven effective in improving their living conditions, but poor compliance results in relapses and rehospitalizations for the majority of patients, which often results in a worsening of residual symptoms. The prevention of these relapses is a major issue in the care of these patients and frequent monitoring is necessary. The use of a simple, rapid and inexpensive tool to monitor symptoms and treatment effect in schizophrenia could improve the effectiveness of the treatment of these patients and prevent relapses. Speech is a good candidate as a biomarker in the monitoring of patients with schizophrenia. Schizophrenia is accompanied by speech disorders including poor speech, variations in tone or intensity or even difficulties in organizing speech.
Trial Details
NCT Number NCT06613334
Lead Sponsor Centre Hospitalier St Anne
Conditions
(from sponsor)		 Schizophrenia
Related terms Schizophrenia
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov